A Study of DS-9606a in Patients With Advanced Solid Tumors

Ovarian Cancer Clinical Trial

Official title:

A Phase 1, First-in-Human Study of DS-9606a in Patients With Tumor Types Known to Express Claudin-6 (CLDN6)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05394675
• Other study ID #: DS9606-137
• Secondary ID: 2022-000120-38RE
• Status: Recruiting
• Phase: Phase 1
• Start date: May 31, 2022
• Est. completion date: February 19, 2026

Study information

• Verified date: January 2024
• Source: Daiichi Sankyo, Inc.
• Contact: Contact for Clinical Trial Information
• Phone: 908-992-6400
• Email: CTRinfo[@]dsi.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will assess the safety and tolerability of DS-9606a in patients with advanced solid tumors.

Description:

This first-in-human, phase 1 study will consist of 2 parts. In Part A (Dose Escalation), the primary objectives will be to investigate the safety and tolerability of DS-9606a in advanced solid tumors and to determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE). In Part B (Dose Expansion), the safety and tolerability of DS-9606a will be further explored and the overall response rate will be assessed. The secondary objectives of the study will assess pharmacokinetic properties of DS-9606a and investigate the duration of response and progression-free survival of DS-9606a, and assess the immunogenicity of DS-9606a.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 125
• Est. completion date: February 19, 2026
• Est. primary completion date: February 19, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• At least 18 years old at the time of written informed consent
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
• Availability of archived tumor tissue samples (mandatory); patients with germ cell tumors without archived tumor samples may be allowed with approval
• Has a left ventricular ejection fraction (LVEF) =50% as determined by either an echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 28 days before the start of study treatment
• Adequate bone marrow and organ function within 7 days before the start of study treatment
• Life expectancy =3 months
• Adequate treatment washout period prior to start of study treatment
• Male patients with female partners of childbearing potential and female patients of child-bearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study for at least 4 months (for males) and for at least 7 months (for females) after the last dose of study drug. Males must agree not to freeze or donate sperm throughout the study period for at least 4 months after final administration of study drug. Females must agree not to donate or retrieve ova for own use throughout the study period and for at least 7 months after final study drug administration.

Dose Escalation Participants Only:

• Histologically- or cytologically-documented locally advanced or metastatic cancers, including but not limited to: ovarian cancer (including fallopian tube and primary peritoneal carcinoma), germ cell tumors, uterine and endometrial cancers, pancreatic adenocarcinoma, non-squamous NSCLC, or gastric cancer
• Disease progression with standard of care therapies for metastatic disease known to confer benefit, or are intolerant to or refuse standard treatment.

Dose Expansion Participants Only:

• Consent to provide pre-treatment (mandatory) and on-treatment tissue biopsy sample (mandatory if not clinically contraindicated)
• Histologically or cytologically-documented locally advanced or metastatic cancers

including:

• Cohort B-1: Ovarian cancer
• Cohort B-2: Refractory germ cell tumors

Exclusion Criteria:

• Has history or current presence of central nervous system metastases, except for participants who have completed radiotherapy or surgery =4 weeks before the start of treatment, and fulfill all criteria (no evidence of disease progression in the CNS and no requirement for chronic corticosteroids) within 2 weeks before the start of treatment
• Other invasive malignancy within 2 years; prior or concurrent non-invasive malignancies and/or patients with localized malignancies that were treated with curative intent who remain disease-free and are considered low likelihood for recurrence may be enrolled
• History of myocardial infarction or unstable angina within 6 months before study treatment
• Has a history of symptomatic congestive heart failure (New York Heart Association classes II-IV) or a serious cardiac arrhythmia requiring treatment
• Has a corrected QT interval by Fridericia's formula (QTcF), of >470 ms based on the average of triplicate 12-lead electrocardiogram (ECG) per local read
• Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required corticosteroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
• Has an uncontrolled infection requiring ongoing or long-term therapy
• Has a known active hepatitis or uncontrolled hepatitis B or C infection

Related Conditions & MeSH terms

• Advanced Cancer
• Germ Cell Tumor
• Metastatic Cancer
• Neoplasm Metastasis
• Neoplasms, Germ Cell and Embryonal
• Ovarian Cancer
• Ovarian Neoplasms

Intervention

Drug:
• DS-9606a
Intravenous infusion

Locations

Country	Name	City	State
United Kingdom	Sarah Cannon Research Institute UK	London
United Kingdom	The Royal Marsden NHS Trust	London
United States	SCRI at HealthONE	Denver	Colorado
United States	Barbara Ann Karmanos Cancer Institute	Detroit	Michigan
United States	MD Anderson Cancer Center	Houston	Texas
United States	SCRI Oncology Partners	Nashville	Tennessee
United States	Florida Cancer Specialists & Research Institute, LLC	Sarasota	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Daiichi Sankyo, Inc.

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with Dose-Limiting Toxicities (DLT) in Participants Receiving DS-9606a		Cycle 1 Day 1 through Day 21 of Cycle 2 (each cycle is 21 days)
Primary	Number of Participants with Treatment-emergent Adverse Events (TEAEs) in Participants Receiving DS-9606a		Cycle 1 Day 1 to 30 days after last dose, up to 36 months (each cycle is 21 days)
Primary	Overall Response Rate of DS-9606a as Assessed by the Investigator in Participants Receiving DS-9606a (Dose Expansion)		Cycle 1 Day 1 and then every 6 weeks for 24 weeks, and then every 12 weeks, up to 36 months (each cycle is 21 days)
Secondary	Pharmacokinetic Parameter Area Under the Plasma Concentration-Time Curve (AUC)		Cycles 1-3, Day 1:pre-dose, end of flush, 4 hours (hr) and 8 hrs post-dose (Cycles 1 and 3 only); Cycle 1 and 3,Day 2; Cycle 1 and 3,Days 4,8, and 15; Cycle 2,Days 8 and 15; Cycle 4,Day 1 and pre-dose every cycle, up to 36 months (each cycle is 21 days)
Secondary	Pharmacokinetic Parameter Maximum Concentration (Cmax)		Cycles 1-3, Day 1:pre-dose, end of flush, 4 hours (hr) and 8 hrs post-dose (Cycles 1 and 3 only); Cycle 1 and 3,Day 2; Cycle 1 and 3,Days 4,8, and 15; Cycle 2,Days 8 and 15; Cycle 4,Day 1 and pre-dose every cycle, up to 36 months (each cycle is 21 days)
Secondary	Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)		Cycles 1-3, Day 1:pre-dose, end of flush, 4 hours (hr) and 8 hrs post-dose (Cycles 1 and 3 only); Cycle 1 and 3,Day 2; Cycle 1 and 3,Days 4,8, and 15; Cycle 2,Days 8 and 15; Cycle 4,Day 1 and pre-dose every cycle, up to 36 months (each cycle is 21 days)
Secondary	Pharmacokinetic Parameter Trough Concentration (Ctrough)		Cycles 1-3, Day 1:pre-dose, end of flush, 4 hours (hr) and 8 hrs post-dose (Cycles 1 and 3 only); Cycle 1 and 3,Day 2; Cycle 1 and 3,Days 4,8, and 15; Cycle 2,Days 8 and 15; Cycle 4,Day 1 and pre-dose every cycle, up to 36 months (each cycle is 21 days)
Secondary	Duration of Response (DoR) as Assessed by the Investigator in Participants Receiving DS-9606a		Cycle 1 Day 1 and then every 6 weeks for 24 weeks, and then every 12 weeks, up to 36 months (each cycle is 21 days)
Secondary	Disease Control Rate (DCR) as Assessed by the Investigator in Participants Receiving DS-9606a		Cycle 1 Day 1 and then every 6 weeks for 24 weeks, and then every 12 weeks, up to 36 months (each cycle is 21 days)
Secondary	Time to Response (TTR) as Assessed by the Investigator in Participants Receiving DS-9606a		Cycle 1 Day 1 and then every 6 weeks for 24 weeks, and then every 12 weeks, up to 36 months (each cycle is 21 days)
Secondary	Progression-free Survival (PFS) as Assessed by the Investigator in Participants Receiving DS-9606a		Cycle 1 Day 1 and then every 6 weeks for 24 weeks, and then every 12 weeks, up to 36 months (each cycle is 21 days)
Secondary	Percentage of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline) and Percentage of Participants Who Have Treatment-emergent ADA		Cycle 1 Days 1 and 15, Cycles 2 and 3 Day 1, Cycle 4 Day 1 and all cycles thereafter on Day 1, up to 36 months (each cycle is 21 days)